Welcome to our dedicated page for Bionano Genomics news (Ticker: BNGO), a resource for investors and traders seeking the latest updates and insights on Bionano Genomics stock.
Bionano Genomics, Inc. reports developments in genome analysis solutions built around optical genome mapping (OGM), diagnostic services, software and nucleic acid extraction technologies. Company updates commonly address OGM applications in cytogenetics, rare disease research, hematologic malignancies, reproductive disorders and other genomic-analysis workflows, including published studies comparing OGM with karyotyping, FISH, chromosomal microarrays, next-generation sequencing and long-read sequencing.
Recurring news also covers financial results, revenue outlooks, scientific-meeting presentations, Bionano Symposium activity, use of VIA™ software, the Ionic® system and Bionano Laboratories diagnostic testing services. Governance updates include board and executive leadership changes at the Nasdaq-listed life sciences instrumentation company.
Bionano Genomics (BNGO) announced a study in Nature highlighting its Saphyr genome imaging technology's role in constructing reference-quality genomes of six bat species. The research shows bats' unique ability to withstand viral infections, relevant amidst the COVID-19 pandemic. Conducted as part of the Bat1K consortium, the study involved a comparative analysis of bat genomes against 42 other mammals, revealing significant genetic adaptations. The findings may advance understanding of viral transmission from bats to humans and the immune mechanisms involved.
Bionano Genomics (BNGO) announced an international consortium using its Saphyr genome imaging system to analyze genomic variants in 1,000 COVID-19 patients across North America and Europe. Led by Dr. Ravindra Kolhe and Dr. Alka Chaubey, the initiative includes over 40 renowned institutions. Initial findings from 30 analyzed patients indicate Saphyr detects significant structural variations in genes linked to disease severity, challenging traditional point mutation theories. Bionano aims to advance COVID-19 understanding and treatment through this collaboration, supported by tech donations from Rescale and Amazon.
Bionano Genomics (BNGO) announced a significant milestone with the first complete assembly of a human chromosome using its genome imaging technology, Saphyr. This assembly, detailed in a Nature publication, showcased the ability to achieve a gap-free build of the human X chromosome. Bionano's technology provided crucial structural accuracy that corrected errors in long-read sequencing data. CEO Erik Holmlin emphasized the potential of this advancement to enhance reference genomes, aiding in the discovery of new therapeutic targets and diagnostic biomarkers.
Bionano Genomics (BNGO) has reported a significant breakthrough in cytogenetic testing through its Saphyr system, achieving 100% concordance with traditional methods in a large study involving 85 samples related to constitutional genetic disorders. Novel fusion genes and mutations were discovered, underscoring Saphyr's potential to replace conventional testing methods in genetic diagnostics. Notably, Saphyr identified a 25% additional yield in unsolved rare diseases. The positive outcomes from these studies may establish Saphyr as the new standard for digital cytogenetic testing.
Bionano Genomics (NASDAQ: BNGO) reported Q1 2020 financials, revealing a total revenue of $1.1 million, down from $1.8 million in Q1 2019. The decline is attributed to lab shutdowns amid COVID-19. The company processed 416 samples in 2020, compared to 212 in 2019, and shipped 116 Saphyr instruments, with 83 installed. Operating expenses rose by 46% to $10 million. The net loss increased to $10.5 million from $7.8 million in the previous year. Cash reserves decreased to $8.1 million as of March 31, 2020. Bionano launched a global study on genomic variants related to COVID-19.
Bionano Genomics, Inc. (NASDAQ: BNGO) has announced a conference call and live webcast on June 18, 2020, at 4:30 p.m. Eastern Time. The call aims to disclose financial results for the first quarter ended March 31, 2020, and provide a business update. Bionano specializes in structural variation detection in genome analysis through its Saphyr® platform. This call will be significant for investors looking to understand the company's performance and future direction.
Bionano Genomics (BNGO) announced a delay in filing its Form 10-Q for Q1 2020 due to the COVID-19 pandemic, with plans to report financial results on June 18, 2020. The company reported preliminary revenue of $1.1 million and cash equivalents of $8.1 million as of March 31, 2020. Bionano is suspending its 2020 guidance amid uncertainties caused by the pandemic. Despite challenges, the company is experiencing increased interest in its Saphyr system, with new placements and ongoing operational capabilities. Recent highlights include fundraising and new collaborations in COVID-19 genomic studies.